Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 322.52 Million SEK | -3.14% |
| 2022 | 332.97 Million SEK | 27.14% |
| 2021 | 261.9 Million SEK | 6.78% |
| 2020 | 245.27 Million SEK | 31.06% |
| 2019 | 187.14 Million SEK | 43.31% |
| 2018 | 130.58 Million SEK | 39.19% |
| 2017 | 93.81 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 298.98 Million SEK | -7.3% |
| 2024 Q2 | 310.51 Million SEK | 3.85% |
| 2023 Q1 | 303.43 Million SEK | -8.87% |
| 2023 Q3 | 304.45 Million SEK | -1.86% |
| 2023 FY | 322.52 Million SEK | -3.14% |
| 2023 Q4 | 322.52 Million SEK | 5.94% |
| 2023 Q2 | 310.21 Million SEK | 2.23% |
| 2022 Q2 | 319.14 Million SEK | 20.88% |
| 2022 FY | 332.97 Million SEK | 27.14% |
| 2022 Q1 | 264.01 Million SEK | 0.81% |
| 2022 Q4 | 332.97 Million SEK | 3.16% |
| 2022 Q3 | 322.79 Million SEK | 1.14% |
| 2021 Q1 | 240.8 Million SEK | -1.82% |
| 2021 Q4 | 261.9 Million SEK | 7.19% |
| 2021 FY | 261.9 Million SEK | 6.78% |
| 2021 Q3 | 244.33 Million SEK | 1.19% |
| 2021 Q2 | 241.47 Million SEK | 0.28% |
| 2020 Q1 | 188.24 Million SEK | 0.59% |
| 2020 FY | 245.27 Million SEK | 31.06% |
| 2020 Q4 | 245.27 Million SEK | 41.16% |
| 2020 Q3 | 173.76 Million SEK | -2.59% |
| 2020 Q2 | 178.38 Million SEK | -5.24% |
| 2019 Q3 | 176.99 Million SEK | -13.81% |
| 2019 Q2 | 205.35 Million SEK | 52.54% |
| 2019 Q1 | 134.62 Million SEK | 3.09% |
| 2019 FY | 187.14 Million SEK | 43.31% |
| 2019 Q4 | 187.14 Million SEK | 5.73% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | 130.58 Million SEK | 39.19% |
| 2018 Q4 | 130.58 Million SEK | 0.0% |
| 2017 FY | 93.81 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -412.89% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 90.189% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 90.189% |
| Arcoma AB | 81.96 Million SEK | -293.507% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 52.77% |
| BICO Group AB (publ) | 10.19 Billion SEK | 96.837% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 57.287% |
| CellaVision AB (publ) | 928.71 Million SEK | 65.272% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -458.728% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -1369.0% |
| C-Rad AB (publ) | 404 Million SEK | 20.167% |
| Duearity AB (publ) | 15.14 Million SEK | -2029.728% |
| Dignitana AB (publ) | 44.83 Million SEK | -619.426% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -209.229% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.415% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -214.236% |
| Iconovo AB (publ) | 128.07 Million SEK | -151.816% |
| Integrum AB (publ) | 164.85 Million SEK | -95.637% |
| Luxbright AB (publ) | 40.68 Million SEK | -692.707% |
| OssDsign AB (publ) | 356.38 Million SEK | 9.502% |
| Paxman AB (publ) | 167.12 Million SEK | -92.985% |
| Promimic AB (publ) | 92.87 Million SEK | -247.269% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -726.015% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -401.331% |
| ScandiDos AB (publ) | 81.47 Million SEK | -295.869% |
| Sectra AB (publ) | 3.21 Billion SEK | 89.955% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 68.194% |
| Senzime AB (publ) | 433.54 Million SEK | 25.607% |
| SpectraCure AB (publ) | 144.83 Million SEK | -122.687% |
| Stille AB | 804.89 Million SEK | 59.929% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 98.032% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 85.31% |